Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

The Bispecific Antibodies Market is projected to grow at a CAGR of 9.5% till 2035, claims Roots Analysis

This image opens in the lightbox

News provided by

Roots Analysis

01 Jun, 2023, 14:45 GMT

Share this article

Share toX

Share this article

Share toX

With the recent approval of Tecvayli™ and other bispecific antibodies, along with the ongoing R&D efforts for evaluating the potential of such candidates against various disease indications, this segment of the pharmaceutic industry has garnered significant interest of stakeholders

LONDON, June 1, 2023 /PRNewswire/ -- Roots Analysis has announced the addition of "Bispecific Antibodies Market, 2023-2035" report to its list of offerings.

Having demonstrated the ability to selectively target various antigens responsible for the development of oncological and non-oncological disorders, a number of bispecific antibodies have so far been evaluated and approved for the treatment of such indications, including the most recent approval of Tecvayli™ in October 2022 for the treatment of multiple myeloma. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results, the bispecific antibodies market is anticipated to grow in the long-run, as multiple drug candidates are expected to receive marketing approval in the coming decade.

To order this 350+ page report, which features 100+ figures and 170+ tables, please visit this link

Key Market Insights

  • 10 bispecific antibody therapeutics have been commercialized and 220+ candidates are currently being evaluated across different stages of clinical development

In terms of clinical stage candidates, more than 45% of the bispecific antibodies are currently being investigated in phase I studies. It is interesting to note that majority of such therapeutics are being evaluated for administration as monotherapy (57%), followed by combination therapies (43%).

Over 30% of the preclinical stage drug candidates are currently being evaluated under IND studies

Majority (>90%) of the candidates in preclinical stage of development are targeting oncology disorders. It is worth mentioning that majority of drug candidates targeting oncological disorders are focused on the treatment of solid tumors (61%), followed by those targeting hematological malignancies (20%).

More than 120 players currently claim to be engaged in the bispecific antibody therapeutics domain

The maximum number of players providing such therapies are small companies (2-50 employees, 37%), followed by mid-sized players (51-500 employees, 35%). Additionally, over 45% of the developers are based in North America, followed by those headquartered in Asia (29%).

70+ bispecific antibody therapeutics are being developed by big pharma players, across the globe

Most of the big pharma players are primarily focused on targets, such as CD20 x CD3 (31%) and PD-L1 x TGFβ (19%). It is important to highlight that over 50% of the drug candidates developed by such players are based on the mechanism of t-cell retargeting / activation.

Partnership activity in this market increased at a CAGR of nearly 35%, over the past seven years

It is worth mentioning that over 40 partnerships have been signed since January 2022. Product development and commercialization agreements have emerged as the most popular (30%) types of agreements inked between the players engaged in this domain.

More than 37,000 patients have been enrolled in close to 280 clinical trials across the globe

Clinical research activity, in terms of the number of trials registered, is reported to have increased over the last five years. Of the total number of trials, close to 80% of studies are active and recruiting patients, while about 20% have already been completed. It is worth mentioning that the majority (50%) of the drug candidates are currently being evaluated in phase I studies.

Players based in North America are anticipated to capture over 60% of the market share by 2035

The market in China / broader Asia-Pacific region is anticipated to grow at a relatively faster pace in the foreseen future. With a promising development pipeline and encouraging clinical results, bispecific antibodies targeting genetic disorders (32%) and hematological malignancies (30%) are expected to capture the major share of the total market in 2035. 

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

  • What is the overall size of the global bispecific antibody therapeutics market?
  • What is the rate at which the bispecific antibodies market is likely to grow in the coming years?
  • Which region has the highest growth rate in the bispecific antibodies market?
  • Who are the leading players engaged in this market?
  • How many players are engaged in developing bispecific antibodies?
  • What are the most common antigens being targeted by bispecific antibody therapeutics?
  • Which target indication covers the largest share in bispecific antibodies market?
  • What is the partnership and collaboration trend in the bispecific antibodies domain?
  • What are the upcoming trends in bispecific antibody therapeutics market?

The financial opportunity within the bispecific antibodies market has been analyzed across the following segments:

  • Therapeutic Area
    • Autoimmune Disorders
    • Genetic Disorders
    • Hematological Malignancies
    • Ophthalmic Disorders
    • Skin Cancers
    • Solid Tumors
  • Mechanism of Action
    • Cytokines Retargeting / Neutralization
    • Dual Ligands Blocking
    • Resistance Factors Co-Targeting
    • Targeting Tumor Angiogenesis
    • T-Cell Retargeting / Activation
    • Others
  • Target Antigen
    • C5-Albumin
    • CD20 x CD3
    • CD3 x BCMA
    • CD3 x CD19
    • EGFR x cMET
    • EpCAM x CD3
    • Factor IXa x Factor X
    • gp100 x CD3
    • HER2 x HER2
    • PD-1 x CTLA-4
    • PD-L1 x TGFβ
    • TNF-α x HAS
    • VEGF x DLL4
    • VEGF-A x ANG2
  • Antibody Format
  •  
    • Asymmetric
    • Fragments
  • Key Players
  •  
    • Akeso Biopharma
    • Alexion
    • Amgen
    • Genmab
    • Immunocore
    • Janssen Research & Development
    • LintonPharm
    • Merck
    • OncXerna Therapeutics
    • Pfizer
    • Roche
    • Taisho Pharmaceutical
    • Zymeworks
  • Key Geographical Regions
  •  
    • Asia
    • Europe
    • North America
    • Rest of the World

The report features inputs from eminent industry stakeholders, according to whom, bispecific antibody therapeutics are expected to be the next big step in cancer immunotherapy. The report includes detailed transcripts of discussions held with the following experts:

  • Ran Salomon (Senior Scientist, Immunai)
  • Francesca Rosato (PhD Student, University of Freiburg)
  • Ludger Große-Hovest (Founder and Chief Scientific Officer, SYNIMMUNE) and Martin Steiner (Chief Executive Officer, SYNIMMUNE)
  • Siobhan Pomeroy (Former Senior Director, Business Development, CytomX Therapeutics)
  • Jane Dancer (Business Development Consultant, F-star)
  • Yinjue Wang (Director, GMP Clinical Manufacturing, Innovent Biologics)

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial information, about bispecific antibody portfolio, recent developments and an informed future outlook.

  • Akeso Biopharma
  • Alphamab Oncology
  • Amgen
  • Merck
  • Regeneron
  • Roche
  • Xencor

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

  1. Global Antibiotics Market: Industry Trends and Global Forecast, 2023-2035
  2. Global TIL Therapies Market (2nd Edition): Industry Trends and Global Forecast, 2023-2035
  3. Global TCR Therapy Market (2nd Edition): Industry Trends and Global Forecast, 2023-2035
  4. Exosome Therapeutics Market: Industry Trends and Global Forecast, 2022-2040
  5. CAR-T Cell Therapy Market (4th Edition): Industry Trends and Global Forecast, 2022-2035

Contact:

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com

Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.